Confronto
CJC-1295 vs. GHRP-6
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Crescita
Crescita
N. CAS
nessun dato
87616-84-0
Peso molecolare
3647.3 g/mol
873.02 g/mol
Emivita
144 h
0.4 h
Sequenza
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACHis-D-Trp-Ala-Trp-D-Phe-Lys-NH2Meccanismo d'azione
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Base di evidenze
Evidenza più alta
Studio sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
3
2
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
3
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between CJC-1295 and GHRP-6?
- CJC-1295 is classified as "Crescita", while GHRP-6 is classified as "Crescita". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. GHRP-6: Synthetic hexapeptide that founded the class of growth-hormone-releasing peptides (GHRPs). Cyril Bowers identified GHRP-6 in the late 1970s as the first orally and parenterally active GH secretagogue with no structural similarity to GHRH. Never approved as a medicine; downstream analogs (GHRP-2, hexarelin, ipamorelin) were pursued clinically. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CJC-1295 or GHRP-6?
- The highest available evidence level is "Studio sull'uomo" for CJC-1295 and "Studio sull'uomo" for GHRP-6. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CJC-1295 and GHRP-6 in Germany and the United States?
- Germania: CJC-1295 — Non approvato, GHRP-6 — Non approvato. Stati Uniti: CJC-1295 — Solo ricerca, GHRP-6 — Non approvato. These are factual summaries with source and review date on the individual pages.